|
|
|
|
|
|
|
12.10.26 - 18:03
|
FR Regulatory News: BIOSYNEX SA (EQS)
|
|
|
BIOSYNEX SA: BIOSYNEX annonce sa sortie de procédure de sauvegarde à la suite de l'arrêté de son plan de sauvegarde par le Tribunal Judiciaire de Strasbourg en date du 12 octobre 2026...
|
|
|
|
|
12.10.26 - 17:48
|
Eurofins Scientific SE: Weekly Report on Share Repurchases from 05th October to 9th October 2026 (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific SE (Paris:ERF):
Name of the Issuer
Identify code of the Issuer
Transaction day
Identify code of the financial instrument
Total daily volume (in number of shares)
Daily weighted average purchase price of the shares
Market (MIC Code)
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
05/10/2026
FR0014000MR3
15 000
75.8464
CEUX
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
05/10/2026
FR0014000MR3
35 000
75.8683
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
06/10/2026
FR0014000MR3
30 000
77.5393
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
07/10/2026
FR0014000MR3
20 000
76.2256
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
07/10/2026
FR0014000MR3
10 000
76.2036
CEUX
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
08/10/2026
FR0014000MR3
10 000
76.1326
CEUX
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
08/10/2026
FR0014000MR3
20 000
76.1620
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
09/10/2026
FR0014000MR3
20 000
76.6227
XPAR
EUROFINS SCIENTIFIC
529900JEHFM47DYY3S57
0...
|
|
|
|
|
12.10.26 - 08:24
|
Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic (Business Wire)
|
|
|
Shareholder approval and settlement and delivery of the capital increases related to the Acquisition
The Acquisition marks a major milestone in Valerio's strategy to build a leading integrated platform to support progress toward the clinic
€40.25 million financing secured in August 2026 supports Etherna's integration and the next development milestones
VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News
Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the completion of the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). Further to the closing of the cash consideration of the Acquisition which occurred in August1, the Company has now proceeded to the settlement of the share consideration, marking the last step of the Acquisition.
The Acquisition marks a major milest...
|
|
|
12.10.26 - 07:36
|
Advicenne Extends Its Cash Runway to 2028 Through Bond Financing and Strong Operational Performance (Business Wire)
|
|
|
€1 million in net cash proceeds received from the remaining tranche of the financing agreement signed with a fund managed by L1 Capital in June 2026.
Financial runway extended to 2028, strengthened by strong products sales both in neurology and nephrology and disciplined management of the Company's resources.
PARIS--(BUSINESS WIRE)--Regulatory News:
Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that it has received the remaining tranche of the financing, with a net amount of €1.0 million, under the bond financing agreement entered into with a fund managed by L1 Capital1.
Following this additional funding, Advicenne has strengthened its cash position, which stood at €1.55 million as of 30 June 2026, and secured its financial runway to 2028, compared with the previously estimated second quarter of 2027. This extension is further st...
|
|
|
|
|
|
|
|
|
09.10.26 - 11:42
|
Eurofins Scientific: Director/PDMR Shareholding (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (Paris:ERF) (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Analytical Bioventures S.C.A (RCS B89265)
23, Val Fleuri, L-1526 Luxembourg
2.
Reason for the notification
a)
Position / status
Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin
b)
Initial notification / amendment
Initial
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Eurofins Scientific S.E.
b)
LEI...
|
|
|
08.10.26 - 19:54
|
Mauna Kea Technologies Announces 2026 Half-Year Results (Business Wire)
|
|
|
Product and service revenue of €3.2 million, up 37% driven by strong CellTolerance® momentum in Europe and new international markets
Gross margin on product and service revenue of 65%, up 2 points
Operating expenses1 of €5.9 million, with R&D and G&A slightly down
Financial visibility extended to the end of 2027 with the renewed support of long-term shareholder and partner Vester FinancePARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reports its consolidated results for the first half of 2026, as approved by the Board of Directors on September 28, 2026. The half-year financial report will be available on the Company's website.
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: "The first half of 2026 was consistent with our roadmap. Growth was driven by CellTolerance®, with dynamic sales in Euro...
|
|
|
08.10.26 - 18:00
|
SpineGuard Announces Its Q3 Revenue (Business Wire)
|
|
|
A +22% increase in the total number of units sold during the period
Sales growing +25% outside the United States
A return to volume growth in the United States and confirmation of operational synergies with Omnia Medical
PARIS--(BUSINESS WIRE)--Regulatory News:
SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today announces its third quarter 2026 revenue.
Pierre Jérôme, Co-founder, Chairman and CEO of SpineGuard, stated:
“The third quarter marks an important milestone for SpineGuard with a +22% increase in the number of units sold worldwide, driven by strong momentum in the various geographic regions where we operate through our commercial partners.
In the United States, unit sales are rising again, driven by orders from Omnia Medical, which are becoming more consistent and substantial. The commercial synergies we sought by transferring the assets o...
|
|
|
|
|
|
|
08.10.26 - 13:09
|
Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and Quality (PR Newswire)
|
|
|
Eli Lilly and Company, Pfizer, Sanofi, UCB, and more share learnings speeding drug development, connecting trials, and modernizing quality and manufacturing PLEASANTON, Calif., Oct. 8, 2026 /PRNewswire/ -- At Veeva R&D and Quality Summit on October 20-21 in Boston, Veeva Systems (NYSE:......
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
